Annovis Bio (ANVS) investor relations material

Executive summary

• Special meeting postponed from October 14 to November 3, 2026, at 10:00 a.m.; September 4, 2026 record date remains unchanged.

• Proposal 1 was narrowed to a common-share authorization increase; the revised voting threshold and broker discretion were clarified.

• Previously submitted proxies remain valid as directed unless stockholders choose to change their votes.

Voting matters and shareholder proposals

• Proposal 1 seeks to increase authorized common shares from 70 million to 140 million; the board recommends FOR.

• Proposal 1 passes if votes cast for exceed votes cast against; abstentions and broker non-votes have no impact, and brokers may vote on this routine matter.

• Proposal 2 seeks ratification of the previously presented amendment to the Option Plan increasing authorized plan shares; Proposal 3 seeks adjournment, if needed, to solicit proxies. The board recommends FOR both.

• Proposal 2 requires voting instructions for shares held by a broker or nominee; internet and telephone votes are due November 2, 2026, at 11:59 p.m. ET.

Board of directors and corporate governance

• The board unanimously recommends approval of Proposal 1, citing financing flexibility, share reserves for outstanding warrants and options, equity awards, and other corporate purposes.

• The board says additional common-share authorization may support capital for ongoing and future clinical trials and research; it is not tied to a planned merger, acquisition, or similar transaction.